高瓴、正心谷出手！“资深专业机构投资者”，再现科创板！

Core Viewpoint - Core Medical has submitted its IPO prospectus for the Sci-Tech Innovation Board, marking a significant step in its capital market journey [1] Group 1: Institutional Investors - The prospectus reveals that Core Medical has recognized Hillhouse Capital and Zhengxin Valley Investment as senior professional institutional investors, making it the first Sci-Tech Innovation Board IPO to have two such investors simultaneously since the trial implementation of this system in June [2] - Hillhouse Capital, managing over 10 billion, has maintained a shareholding of over 3% in Core Medical for more than 24 months, with seven of its invested tech companies listed on the Sci-Tech Innovation Board in the past five years [4] - Zhengxin Valley Investment, also managing over 10 billion, has similarly held over 3% of Core Medical's shares for more than 24 months, with five of its tech investments listed on the Sci-Tech Innovation Board in the last five years [4] Group 2: Regulatory Background - In June, the China Securities Regulatory Commission (CSRC) introduced the senior professional institutional investor system for companies applying under the fifth listing standard of the Sci-Tech Innovation Board, aiming to enhance the identification of quality tech firms and improve the overall quality of listed companies [6] - The introduction of this system is a pilot program, specifically targeting companies under the fifth listing standard, and the involvement of senior professional institutional investors will serve as a reference for the review process rather than a new listing requirement [7] - The Shanghai Stock Exchange has established guidelines for recognizing senior professional institutional investors, encouraging companies to voluntarily disclose this information while ensuring that the review standards remain stringent [8]